rs587782085
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM5_SupportingPM3PM2_SupportingPVS1
This summary comes from the ClinGen Evidence Repository: The c.1158del p.Lys387Argfs*3 variant in ATM is a frameshift variant in a biologically-relevant-exon predicted to cause a premature stop codon leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism. This alteration results in a termination codon upstream of the most C-terminus pathogenic alteration (ATM p.Arg3047*), as classified by the HBOP VCEP, and is expected to be more deleterious. This variant is absent from gnomAD v2.1.1. This variant has been detected in at least 3 individuals with Ataxia-Telangiectasia (PMID:10234507, 26896183, 19147735). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant hereditary breast cancer and autosomal recessive Ataxia-Telangiectasia based on the ACMG/AMP criteria applied, as specified by the HBOP VCEP (PVS1, PM2_Supporting, PM3, PM5_supporting). LINK:https://erepo.genome.network/evrepo/ui/classification/CA166706/MONDO:0016419/020
Frequency
Consequence
NM_000051.4 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.1158delG | p.Lys387fs | frameshift_variant | 9/63 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.00000342 AC: 5AN: 1461728Hom.: 0 Cov.: 33 AF XY: 0.00000138 AC XY: 1AN XY: 727172
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Ataxia-telangiectasia syndrome Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 11, 2021 | This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in an individual affected with ataxia-telangiectasia (PMID: 10234507). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 141887). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Lys387Argfs*3) in the ATM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 28, 2019 | Variant summary: ATM c.1158delG (p.Lys387ArgfsX3) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (c.1339C>T, p.Arg447X; c.1564_1565delGA, p.Glu522fsX43; c.2502dupA, p.Val835fsX7). The variant was absent in 251274 control chromosomes (gnomAD). The variant, c.1158delG, has been reported in the literature in multiple individuals affected with Ataxia-Telangiectasia (Izatt_1999, Thompson_2005, Nahas_2009, Schon_2019). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three ClinVar submissions from other clinical diagnostic laboratories (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Familial cancer of breast Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Sep 26, 2023 | - - |
Pathogenic, reviewed by expert panel | curation | ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Variant Curation Expert Panel, ClinGen | Jan 25, 2024 | The c.1158del p.Lys387Argfs*3 variant in ATM is a frameshift variant in a biologically-relevant-exon predicted to cause a premature stop codon leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism. This alteration results in a termination codon upstream of the most C-terminus pathogenic alteration (ATM p.Arg3047*), as classified by the HBOP VCEP, and is expected to be more deleterious. This variant is absent from gnomAD v2.1.1. This variant has been detected in at least 3 individuals with Ataxia-Telangiectasia (PMID: 10234507, 26896183, 19147735). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant hereditary breast cancer and autosomal recessive Ataxia-Telangiectasia based on the ACMG/AMP criteria applied, as specified by the HBOP VCEP (PVS1, PM2_Supporting, PM3, PM5_supporting). - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Jan 12, 2024 | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. - |
Hereditary cancer-predisposing syndrome Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 13, 2021 | The c.1158delG pathogenic mutation, located in coding exon 8 of the ATM gene, results from a deletion of one nucleotide at nucleotide position 1158, causing a translational frameshift with a predicted alternate stop codon (p.K387Rfs*3). This mutation has been identified in trans with another ATM mutation in patients with ataxia-telangiectasia (Izatt L et al. Eur. J. Hum. Genet., 1999 Apr;7:310-20; Schon K et al. Ann Neurol, 2019 02;85:170-180). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | May 13, 2020 | This variant deletes 1 nucleotide in exon 9 of the ATM gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. Functional studies have shown that this variant impaired DNA repair response (PMID: 19147735). This variant has been reported in individuals affected with ataxia telangiectasia in compound heterozygous state. (PMID: 10234507, 15928302, 19147735). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of ATM function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 04, 2015 | This deletion of one nucleotide in ATM is denoted c.1158delG at the cDNA level and p.Lys387ArgfsX3 (K387RfsX3) at the protein level. The normal sequence, with the base that is deleted in braces, is AAAG[G]AAGA. The deletion causes a frameshift, which changes a Lysine to an Arginine at codon 387, and creates a premature stop codon at position 3 of the new reading frame. This variant is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. ATM c.1158delG has been reported in at least three patients with a clinical diagnosis of Ataxia telangiectasia (Izatt 1999, Thompson 2005). we consider this variant to be pathogenic. The presence of - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at